Fig. 5.

Forest plot of progression-free survival (PFS) to determine the association of patient baseline factors of interest with PFS with IRd treatment. A univariate Cox proportional hazard model was used to estimate the hazard ratios for risk of PFS. ^aClinical relapse was defined as disease recurrence with CRAB (i.e., calcium elevation, renal insufficiency, anemia, and bone abnormalities) symptoms. ^bParaprotein relapse was defined as disease recurrence with elevated M-protein levels but without CRAB symptoms. ^cHigh-risk was defined as the presence of ≥ 1 of t(4;14), t(14;16), or del(17p). ^dStandard-risk was defined as the absence of high-risk cytogenetic abnormalities. CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem-cell transplantation; IRd, ixazomib + lenalidomide + dexamethasone